Subitec GmbH, a manufacturer of fully automated algae photobioreactors, hascloseda second round of financing. The CleantechFonds of eCAPITAL entrepreneurial Partners AG, Fraunhofer Venture, High-Tech Gründerfonds (HTGF) [High-Tech Start-Up Fund] and KfWBankengruppe’s ERP-Startfonds [ERP Sta ... more
Subitec raises 4.5 m euros in second round financing
Subitec GmbH, a manufacturer of fully automated algae photobioreactors, hascloseda second round of financing. The CleantechFonds of eCAPITAL entrepreneurial Partners AG, Fraunhofer Venture, High-Tech Gründerfonds (HTGF) [High-Tech Start-Up Fund] and KfWBankengruppe’s ERP-Startfonds [ERP Start Fund] participated in the capital increase. Subitec funds to the amount of 4.5 m euros will accrue in this round of financing. The raised capital is to be used mainly for launching bioreactors on the international market and to extend technological leadership.
“Compared to other energy crops such as maize or wheat, algae are considerably more efficient in creating biomass. To exploit this potential, Subitec has developed highly efficient algae photobioreactors which permit the propagation of algae and the creation of algae biomass at competitive prices on an industrial scale. Together we would now like to encourage the further development of this innovative company”, says Dr Michael Lübbehusen, Managing Partner of eCAPITAL AG. The capital made available would enable Subitec to further extend its market position. Among other things, source materials for the chemical, pharmaceutical and food industries can be obtained from the microalgae.
Lübbehusen further adds that Subitec is making the fully automated operation of algae photobioreactors possible with its patented flat panel airlift process. The creation of biomass is not in competition with food production here. Subitec’s reactors can be operated at locations where no other form of farming is possible.
Subitec will use the funds from the capital increase among other things to develop the fourth generation of the flat panel airlift reactor (FPA). “The collaboration with our new investors enables us to address international markets and further extend our technological leadership”, explains Dr Peter Ripplinger, Managing Director of Subitec GmbH, on the occasion of the recent closing. Subitec was founded in 2000 as a spin-off of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB.
The photobioreactor developed by Subitec GmbH enables efficient production of algae biomass on an industrial scale. Microalgae such as the freshwater algae Haematococcuspluvialis or the diatom Phaeodactylumtricornutum can for example provide fatty acids, proteins, vitamins, carotenoids and colorants. Among other things, these are needed as primary products for the production of cosmetics, food additives and animal feed.
Conventional algae cultivation in Asia takes place mainly in open ponds. The Subitec algae bioreactor in contrast allows land-based cultivation in closed bioreactors without water loss from evaporation. It can also be operated sterilely, i.e. under conditions essential for the pharmaceutical and cosmetics industries.
Two early-stage venture capital investors are joining the i3 Membrane GmbH startup in August 2014. High-Tech Gründerfonds (HTGF) of Bonn and Innovationsstarter Fonds of Hamburg are investing in development and marketing of a novel filter technology. The new high-tech membrane is made of hig ... more
Predemtec GmbH develops a blood test for a reliable diagnosis of Alzheimer’s disease. In July 2014 the start-up received a seed financing from High-Tech Gruenderfonds (HTGF). The seed investment will be used to finalize the first test into a marketable product and to expand the scope of the ... more
AyoxxA Biosystems announced it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF – High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive ... more
- The architecture of odor perception
- Cellular Mechanism Provides Explanation Model for Declining Memory Performance in Alzheimer's Disease
- Ulrich Krauss to succeed Analytik Jena founder Klaus Berka as CEO
- Merck announces 2016 recipients of € 1 Million grant for Multiple Sclerosis Innovation
- Measuring forces in the DNA molecule